English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
 Local TagsRelease HistoryDetailsSummary
  Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients

Bahner, D., Klucke, C., Kitze, B., Elitok, E., Bogumil, T., Dressel, A., et al. (2002). Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients. Neuroscience Letters, 326(2), 125-128.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-000E-A1C1-C Version Permalink: https://hdl.handle.net/11858/00-001M-0000-000E-A1C2-A
Genre: Journal Article
Alternative Title : Neurosci. Lett.

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Bahner, D1, Author
Klucke, C1, Author
Kitze, B1, Author
Elitok, E1, Author
Bogumil, T1, Author
Dressel, A1, Author
Tumani, H1, Author
Weber, F1, Author
Poser, S1, Author
Bitsch, A-1, Author
Affiliations:
1Max Planck Institute of Psychiatry, Max Planck Society, ou_1607137              

Content

show
hide
Free keywords: primary progressive multiple sclerosis; interferon-beta-1b; interleukin-12; cytokines
 Abstract: Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNbeta-1b, Betaferon(TM), eight million units (MIU) every other day subcutaneously). Median IL-12p40 levels in MS patients before treatment (66.5 and 63.9 pg/ml) were not elevated compared to 18 healthy controls. IL-12p40 significantly increased during treatment (P < 0.0001, median 105.3 pg/ml after 1 month and 95.3 pg/ml after 3 months). Detectable serum levels of IL-12p70 before therapy were only found in one patient. IL-12p70 did not increase during treatment. These data show that immunological processes may also play a role in primary progressive MS and that IFNbeta-1b has an immunomodulating effect in this particular MS subtype. (C) 2002 Published by Elsevier Science Ireland Ltd

Details

show
hide
Language(s): eng - English
 Dates: 2002-06-28
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 4126
ISI: 000176623000014
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Neuroscience Letters
  Alternative Title : Neurosci. Lett.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 326 (2) Sequence Number: - Start / End Page: 125 - 128 Identifier: ISSN: 0304-3940